Mouse models of colorectal cancer and liver metastases

Digestive Surgery

Volumn 22, Issue 1-2, 2005, Pages 16-25

  Heijstek, M W ^a   Kranenburg, O ^a   Rinkes, I H M Borel ^a,b  

^a Utrecht Stroke Center   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Colorectal cancer; Liver metastases; Mouse model; Optical imaging; Small animal imaging; Tumor model

Indexed keywords

LUCIFERASE;

BIOLUMINESCENCE; CARCINOGENESIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DNA DAMAGE; GENE INACTIVATION; GENE MUTATION; GENETIC ENGINEERING; HEREDITY; HISTOLOGY; HUMAN; IMPLANTATION; INTESTINE TUMOR; LIVER METASTASIS; MISMATCH REPAIR; NONHUMAN; ONCOGENE; REVIEW; TUMOR BIOPSY;

ANIMALS; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE MODELS, ANIMAL; GENES, APC; GENETIC ENGINEERING; GERM-LINE MUTATION; LIVER NEOPLASMS; LUCIFERASES; MICE; NEOPLASM INVASIVENESS;

EID: 19944424487     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085342     Document Type: Review

References (64)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
2. Hann B, Balmain A: Building 'validated' mouse models of human cancer. Curr Opin Cell Biol 2001;13:778-784.
3. Rosenberg MP, Bortner D: Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer). Cancer Metast Rev 1998;17:295-299.
4. Anisimov VN, Zabezhinski MA, Rossolini G, Zaia A, Piantanelli A, Basso A, Piantanelli L: Long-live euthymic BALB/c-nu mice. II. Spontaneous tumors and other pathologies. Mech Age Dev 2001;122:477-489.
5. Chandra M, Frith CH: Spontaneous neoplasms in aged CD-1 mice. Toxicol Lett 1992;61:67-74.
6. Kobaek-Larsen M, Thorup I, Diederichsen A, Fenger C, Hoitinga MR: Review of colorectal cancer and its metastases in rodent models: Comparative aspects with those in humans. Comp Med 2000;50:16-26.
7. Yang J, Shikata N, Mizuoka H, Tsubura A: Colon carcinogenesis in shrews by intrarectal infusion of N-methyl-N-nitrosourea. Cancer Lett 1996;110:105-112.
8. Peltomaki P: Deficient DNA mismatch repair: A common etiologic factor for colon cancer. Hum Mol Genet 2001;10:735-740.
9. Bulow S, Faurschou NT, Bulow C, Bisgaard ML, Karlsen L, Moesgaard F: The incidence rate of familial adenomatous polyposis. Results from the Danish Polyposis Register. Int J Colorectal Dis 1996;11:88-91.
10. Edelmann W, Yang K, Kuraguchi M, Heyer J, Lia M, Kneitz B, Fan K, Brown AM, Lipkin M, Kucherlapati R: Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Res 1999;59:1301-1307.
11. de Wind N, Dekker M, van Rossum A, van der Valk M, te Riele H: Mouse models for hereditary nonpolyposis colorectal cancer. Cancer Res 1998;58:248-255.
12. Prolla TA, Baker SM, Harris AC, Tsao JL, Yao X, Bronner CE, Zheng B, Gordon M, Reneker J, Arnheim N, Shibata D, Bradley A, Liskay RM: Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet 1998; 18:276-279.
13. Reitmair AH, Redston M, Cai JC, Chuang TC, Bjerknes M, Cheng H, Hay K, Gallinger S, Bapat B, Mak TW: Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice. Cancer Res 1996;56:3842-3849.
14. de Wind N, Dekker M, Berns A, Radman M, te Riele H: Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995;82: 321-330.
15. Fodde R, Edelmann W, Yang K, van Leeuwen C, Carlson C, Renault B, Breukel C, Alt E, Lipkin M, Khan PM: A targeted chain-termination mutation in the mouse Ape gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 1994;91:8969-8973.
16. Williamson SL, Kartheuser A, Coaker J, Kooshkghazi MD, Fodde R, Burn J, Mathers JC: Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis 1999;20: 805-810.
17. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-5044.
18. Corpet DE, Pierre F: Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
19. Donehower LA: The p53-deficient mouse: A model for basic and applied cancer studies. Semin Cancer Biol 1996;7:269-278.
20. Macleod KF, Jacks T: Insights into cancer from transgenic mouse models. J Pathol 1999; 187:43-60.
21. Zhu Y, Richardson JA, Parada LF, Graff JM: Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998;94:703-714.
22. Clarke AR: Manipulating the germline: Its impact on the study of carcinogenesis. Carcinogenesis 2000;21:435-441.
23. Jackson-Grusby L: Modeling cancer in mice. Oncogene 2002;21:5504-5514.
24. Jonkers J, Berns A: Conditional mouse models of sporadic cancer. Nat Rev Cancer 2002;2: 251-265.
25. Lewandoski M: Conditional control of gene expression in the mouse. Nat Rev Genet 2001;2: 743-755.
26. Meuwissen R, Jonkers J, Berns A: Mouse models for sporadic cancer. Exp Cell Res 2001;264: 100-110.
27. Tuveson DA, Jacks T: Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 2002;12:105-110.
28. Van Dyke T, Jacks T: Cancer modeling in the modern era: Progress and challenges. Cell 2002;108:135-144.
29. Shibata H, Toyama K, Shioya H, Ito M, Hirota M, Hasegawa S, Matsumoto H, Takano H, Akiyama T, Toyoshima K, Kanamaru R, Kanegae Y, Saito I, Nakamura Y, Shiba K, Noda T: Rapid colorectal adenoma formation initiated by conditional targeting of the Ape gene. Science 1997;278:120-123.
30. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, Taketo MM: Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 1999; 18:5931-5942.
31. Harada N, Miyoshi H, Murai N, Oshima H, Tamai Y, Oshima M, Taketo MM: Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res 2002;62: 1971-1977.
32. Kerbel RS: What is the optimal rodent model for anti-tumor drug testing? Cancer Metast Rev 1998;17:301-304.
33. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH: c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001;61:4910-4915.
34. Bankert RB, Egilmez NK, Hess SD: Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 2001;22:386-393.
35. Fu X, Herrera H , Kubota T, Hoffman RM: Extensive liver metastasis from human colon cancer in nude and seid mice after orthotopic onplantation of histologically-intact human colon carcinoma tissue. Anticancer Res 1992; 12:1395-1397.
36. Fu XY, Besterman JM, Monosov A, Hoffman RM: Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci USA 1991;88:9345-9349.
37. Pocard M, Tsukui H, Salmon RJ, Dutrillaux B, Poupon MF: Efficiency of orthotopic xenograft models for human colon cancers. In Vivo 1996;10:463-469.
38. Kuo TH, Kubota T, Watanabe M, Furukawa T, Teramoto T, Ishibiki K, Kitajima M, Moossa AR, Penman S, Hoffman RM: Liver colonization competence governs colon cancer metastasis. Proc Natl Acad Sci USA 1995;92: 12085-12089.
39. Bresalier RS, Raper SE, Hujanen ES, Kim YS: A new animal model for human colon cancer metastasis. Int J Cancer 1987;39:625-630.
40. Giavazzi R, Campbell DE, Jessup JM, Cleary K, Fidler IJ: Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res 1986;46:1928-1933.
41. Kubota T: Metastatic models of human cancer xenografted in the nude mouse: The importance of orthotopic transplantation. J Cell Biochem 1994;56:4-8.
42. Wilmanns C, Fan D, O'Brian CA, Bucana CD, Fidler IJ: Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 1992;52: 98-104.
43. Furukawa T, Kubota T, Watanabe M, Kuo TH, Nishibori H, Kase S, Saikawa Y, Tanino H, Teramoto T, Ishibiki K: A metastatic model of human colon cancer constructed using cecal implantation of cancer tissue in nude mice. Surg Today 1993;23:420-423.
44. Rashidi B, Sun FX, Jiang P, An Z, Gamagami R, Moossa AR, Hoffman RM: A nude mouse model of massive liver and lymph node metastasis of human colon cancer. Anticancer Res 2000;20:715-722.
45. Sun FX, Sasson AR, Jiang P, An Z, Gamagami R, Li L, Moossa AR, Hoffman RM: An ultra-metastatic model of human colon cancer in nude mice. Clin Exp Metastasis 1999;17:41-48.
46. Morikawa K, Walker SM, Jessup JM, Fidler IJ: In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res 1988;48:1943-1948.
47. Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, Ross BD, Rehemtulla A, Lawrence TS: The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther 2002;9:844-849.
48. Matsuda I, Konno H, Tanaka T, Nakamura S: Antimetastatic effect of hepatotropic liposomal adriamycin on human metastatic liver tumors. Surg Today 2001;31:414-420.
49. Dong Z, Radinsky R, Fan D, Tsan R, Bucana CD, Wilmanns C, Fidler IJ: Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 1994;86:913-920.
50. Fidler LT, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D: Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metast Rev 1994;13:209-222
51. Killion JJ, Radinsky R, Fidler IJ: Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metast Rev 1998;17:279-284.
52. Resor L, Bowen TJ, Wynshaw-Boris A: Unraveling human cancer in the mouse: Recent refinements to modeling and analysis. Hum Mol Genet 2001;10:669-675.
53. Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ: Small animal imaging. Current technology and perspectives for oncological imaging. Eur J Cancer 2002;38:2173-2188.
54. Weissleder R: Scaling down imaging: Molecular mapping of cancer in mice. Nat Rev Cancer 2002;2:11-18.
55. Chishima T, Miyagi Y, Wang X, Yamaoka H, Shimada H, Moossa AR, Hoffman RM: Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res 1997;57:2042-2047.
56. Hoffman RM: Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. Cancer Metast Rev 1998;17:271-277.
57. Yang M, Baranov E, Jiang P, Sun FX, Li XM, Li L, Hasegawa S, Bouvet M, Al Tuwaijri M, Chishima T, Shimada H, Moossa AR, Penman S, Hoffman RM: Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci USA 2000; 97:1206-1211.
58. Herzig M, Christofori G: Recent advances in cancer research: Mouse models of tumorigenesis. Biochim Biophys Acta 2002;1602:97-113.
59. Blasco MA: Telomeres in cancer and aging: Lessons from the mouse. Cancer Lett 2003; 194:183-188.
60. Paulsen JE, Steffensen IL, Namork E, Eide TJ, Alexander J: Age-dependent susceptibility to azoxymethane-induced and spontaneous tumorigenesis in the Min/+ mouse. Anticancer Res 2003;23:259-265.
61. Wasan HS, Novelli M, Bee J, Bodmer WF: Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc Natl Acad Sci USA 1997;94:3308-3313.
62. Minamoto T, Mai M, Ronai Z: Environmental factors as regulators and effectors of multistep carcinogenesis. Carcinogenesis 1999;20:519-527.
63. Hursting SD, Perkins SN, Phang JM, Barrett JC: Diet and cancer prevention studies in p53-deficient mice. J Nutr 2001;131(suppl):3092S-3094S.
64. Dreosti IE: Nutrition, cancer, and aging. Ann NY Acad Sci 1998;854:371-377.